ClinicalTrials.gg
CompletedNCT02576041F1Updated Apr 18, 2017Results posted

Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria

A Phase 4 interventional study of Bilastine and Placebo in Allergic Rhinitis and Urticaria, sponsored by Menarini International Operations Luxembourg SA. Completed at 1 site in Italy. Open to participants aged 21 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-04-18.

Sponsored by Menarini International Operations Luxembourg SA (part of Menarini Group) · Phase 4, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Rhinitis, Allergic with a site in Italy — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic · Italy.

Enrollment
14th of 14
19 · median 40
Started
2015
with 5 others
Phase 4
8 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
1 of 22
Menarini International Operations Luxembourg SA

Among the 22 studies in Rhinitis, Allergic with a site in Italy, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 6 that started in 2015, is one of 8 in phase 4, and was the 10th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

None of the 22 studies in Rhinitis, Allergic with a site in Italy is open now. The open studies under Rhinitis, Allergic, anywhere →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Rhinitis, Allergic with a site in Italy as a file.
02

Study summary

The aim of the study is to evaluate the effects of Bilastine on patients' attention and reactivity levels by measuring psychophysical performance at a F1-high speed simulator driving test.

Read the detailed description

This was a phase IV, interventional, prospective, mono-centric, single arm, uncontrolled, open label trial. The study included outpatient affected by Allergic Rhinitis and/or Chronic Urticaria, responding to inclusive criteria and able to perform a preliminary driving test on F1-high speed simulator (at the simulator centre) without experiencing signs or symptoms of intolerance towards the drive simulation (e.g., nausea, vomiting or dizziness etc). Each subject underwent 3 ambulatory visits at the hospital site and 3 driving test at the simulator centre.

03

Conditions studied

  • Allergic Rhinitis
  • Urticaria

Keywords

  • driving simulator
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients affected by allergic rhinitis (seasonal or perennial) or urticaria (induced and not induced) who need histamine H1-receptor antagonist therapy according to PI therapeutic decision;
  • Males and females aged between 21 and 55 years;
  • (BMI) between 19 and 30 kg/m2 (included);
  • If women: negative pregnant test and from at least 30 days before the study (Visit V-1) and up to the end of the study. For women patients the negative pregnant test will be acquired before the Simulator performance (Visit V-1H);
  • Subjects having a valid driving license from more than 3 years;
  • Subjects having a driving experience of at least 5000 km per year;
  • Subjects able to understand the protocol and to come to the visits;
  • Subjects able to give a written ;
  • Subjects who, at investigator's judgment, are likely to be compliant during the study and do not use potentially adulterating drugs;
  • Potential compliant subjects will be enrolled only if they tolerate driving the F1-simulator (starting from V-1 S).

Exclusion criteria

Exclusion Criteria:

  • Subjects with urticaria;
  • to the active substance bilastine or to any of the ;
  • History or symptoms of severe mental or physical disorders or taking substance and alcohol;
  • Excessive smoking (more than 20 cigarettes per day), or consumption of caffeinated beverages (more than 6 cups per day);
  • Subjects who need unimpaired psychophysical condition due to their job;
  • Subjects with any non corrected visual defect or locomotor disorder which could interfere with the study;
  • Subjects ineligible at Visit V-1;
  • Subjects with known allergic reactions to antihistamines;
  • Subjects with porphyria;
  • Subjects with important sleep disturbances or kinetosis;
  • Subjects with (based on Investigator's judgment) renal or hepatic impairment, or gastrointestinal diseases (e.g. malabsorption);
  • Subjects with a medical history of seizure (i.e. epileptic related) or with current seizure;
  • Presence of significant medical condition/concomitant illnesses that, in the opinion of the Investigator, renders the patient or not suitable for a clinical trial or could adversely affect the subject's participation or evaluation in this study;
  • Subjects for whom, in the opinion of the Investigator, there is concern about compliance with the study procedures;
  • Presence of a permanent gastrointestinal condition which may influence the oral therapy (chronic diarrhoea diseases, congenital malformations or surgical mutilations of the gastrointestinal tract);
  • Presence of active cancer which requires chemotherapy or radiation therapy;
  • Presence of alcohol abuse or drug addiction;
  • Pregnancy or breast-feeding;
  • Treatment with: diuretics, (other than medication applied topically), central nervous system medications or medications with sedative effects (sleep inducing or antidepressant, sedative medications), medications that can interact with bilastine, other medications. In particular, patients treated with any of the following drugs will be excluded:

    • Imipramine antidepressants, anticholinergic antiparkinsonians, atropine antispasmodics, disopyramide, phenothiazine neuroleptics;
    • Sedative antidepressants, monoamine oxidase (MAOI) inhibitors, barbiturates, benzodiazepines, clonidine and related substances, hypnotics, morphine derivatives (analgesics, antitussives, replacement treatments), neuroleptics, anxiolytics;
    • Treatments with P-glycoprotein inhibitors (e.g. ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem), which may increase the plasmatic levels of bilastine;
    • Treatments that are substrates or inhibitors of OATP1A2 (e.g. ritonavir, rifampicin), which may decrease plasma concentrations of bilastine
    • Other treatments that can interact with bilastine (e.g. ketoconazole, erythromycin, diltiazem); Treatment with anticoagulants (e.g. warfarin);
    • Sedatives, hypnotics, tranquillizers or any other addictive agents;
    • Other treatments not admitted during the study: betahistine, anticholinesterases, arrhythmogenic drugs;
    • H2-antihistamines;
    • H1 antihistamines other than study medication or rescue medication. In any case, the possibility of inclusion of patients taking any of these drugs will be left at the Investigator's judgment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Placebo (run-in); Bilastine

    At V0, the enrolled patient received the complete drug-kit and started a 7 (+3)-day wash-out period with placebo. At the end of the 7 (+3)-days of placebo-treatment period, patients repeated the F1-high speed simulator test at Visit V1, and afterwards initiated the 7 (+3)-day treatment period with active treatment (bilastine).

    Drug: Bilastine · Drug: Placebo

Interventions

  • Bilastine tablets once a day for 7+3 days

    Also known as: Robilas

  • DrugPlacebo

    Placebo tablets once a day during 7+3 days run in period

06

What researchers measure

Primary outcomes

  1. Standard Deviation Lateral Position (SDLP) Evaluated During the F1 Simulator Test

    SDLP (mainly assessing attention capacities). This is a measure of weaving and quality in keeping the requested path. The vehicle position was constantly monitored. The deviation from central position was registered.

    Time frame: 7+3 days of active treatment

Secondary outcomes

  1. Maintenance of Constant Speed Evaluated During the F1 Simulator

    Different speed were maintained as requested by the simulator. Variations during the test were recorded. The mean deviation from the requested speed was registered.

    Time frame: 7±3 days of active treatment

  2. Time to Reaction Evaluated During the F1 Simulator

    During the test, at different times, the patient will be requested (by led enlighten on the dashboard) to execute actions on the steering-wheel. The delay in executing the requested actions will be registered.

    Time frame: 7±3 days of active treatment

07

Results

Posted Jan 16, 2017

Participant flow

Placebo (run-in)
Participant flow — Placebo (run-in)
MilestonePlacebo (run-in); Bilastine
Started18
Completed18
Not completed0
Bilastine (Active Treatement)
Participant flow — Bilastine (Active Treatement)
MilestonePlacebo (run-in); Bilastine
Started18
Completed18
Not completed0

Outcome measures

PrimaryStandard Deviation Lateral Position (SDLP) Evaluated During the F1 Simulator Test

SDLP (mainly assessing attention capacities). This is a measure of weaving and quality in keeping the requested path. The vehicle position was constantly monitored. The deviation from central position was registered.

Time frame:
7+3 days of active treatment
Reported as:
Mean · meters
Standard Deviation Lateral Position (SDLP) Evaluated During the F1 Simulator Test
metersBilastine
Standard Deviation Lateral Position (SDLP) Evaluated During the F1 Simulator Test-0.041 ± 0.047
SecondaryMaintenance of Constant Speed Evaluated During the F1 Simulator

Different speed were maintained as requested by the simulator. Variations during the test were recorded. The mean deviation from the requested speed was registered.

Time frame:
7±3 days of active treatment
Reported as:
Mean · Km/h
Maintenance of Constant Speed Evaluated During the F1 Simulator
Km/hBilastine
Maintenance of Constant Speed Evaluated During the F1 Simulator-1.397 ± 2.991
SecondaryTime to Reaction Evaluated During the F1 Simulator

During the test, at different times, the patient will be requested (by led enlighten on the dashboard) to execute actions on the steering-wheel. The delay in executing the requested actions will be registered.

Time frame:
7±3 days of active treatment
Reported as:
Mean · msec
Time to Reaction Evaluated During the F1 Simulator
msecBilastine
Time reaction to Button A-34.5 ± 95.71
Time reaction to button B-18.25 ± 66.28

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (run-in); Bilastine—0/18 (0%)18/18 (100%)
Most frequent other events
Most frequent other events
EventPlacebo (run-in); Bilastine
Laboratory test abnormalInvestigations17/18
bradycardiaCardiac disorders1/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo (run-in); Bilastine
Mean38.4 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (run-in); Bilastine
Female8
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo (run-in); Bilastine
Hispanic or Latino18
Not Hispanic or Latino0
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo (run-in); Bilastine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White18
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Placebo (run-in); Bilastine
Italy18
08

Study locations

1 site
  • Azienda Ospedaliero-Universitaria Policlinico
    Modena, Italy
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2015
First posted
Oct 15, 2015
Start
Oct 2015
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Jan 16, 2017
Last update
Apr 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02576041
Responsible party
Sponsor
First posted
Oct 15, 2015
Start date
Oct 2015
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Jan 16, 2017
Last update
Apr 18, 2017

Study contacts

Patrizia Pepe
principal investigator · Allergology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion